Mammalian Cell Culture Metabolite Control Patents: Leaders & Trends 2026
Mammalian cell culture metabolite control patents: who holds the claims on lactate, ammonia and pH regulation
Concentrated but not locked. the top 5 assignees hold 28.4% of the 641 records in scope, and the top 10 hold 44.3% — a discernible core with a long tail behind it. Filings hit 27 in 2017, the peak year in this dataset. The 2021-to-2024 span shows a -83% swing (6 down to 1) — the last year, 2024, is the most recent one the dataset can treat as complete, since publication typically lags filing by around 18 months and 2025-2026 counts will still fill in.
- 1BIOGEN MA INC49
- 2NOVARTIS AG46
- 3INCYTE CORP31
- 4YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD30
- 5SAMSUNG BIOEPIS CO LTD26
See the full mammalian cell culture metabolite control analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents on mammalian cell culture metabolite control?
This dataset ranks 100 companies by record count, with the leading assignee holding 49 of the 641 records in scope and fifth place holding 26. The top 5 combined account for 28.4% of all records and the top 10 for 44.3%, which means the field has a visible core of active filers but well over half the records sit outside that group. Any competitive read should treat this as a concentrated-but-open field rather than one dominated by a single player.
Is patent filing in this space growing or shrinking?
Filing peaked at 27 records in 2017 and has declined since, with a documented -83% swing from 6 records in 2021 to 1 in 2024. 2024 is the most recent year this dataset can treat as complete, because publication typically lags filing by around 18 months, so 2025 and 2026 counts are still filling in and should not yet be read as confirming a continued decline. The honest read is that activity has cooled from its 2017 high, not that it has stopped.
What patent classes cover lactate, ammonia and pH control in cell culture?
The dataset is filtered to C12N5/00 (cell culture and genetic engineering), C12M3/00 (bioreactors and apparatus) and C12Q1/02 (enzyme/microorganism testing methods). Within the results, C12N appears on 89.2% of the 641 records, C07K (peptides and proteins) on 44.5%, and C12M — the apparatus class most directly tied to bioreactor hardware — on only 18.9%. That spread shows most claims are written around the biological or genetic engineering side of metabolite control rather than the physical reactor system.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Mammalian Cell Culture Metabolite Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.